Author of

• 15209

  +

  P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Advanced Diseases - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 15216

    +

    P3.01-007 - Evaluation of Gefitinib Efficacy According to Body Surface Area, Body Weight, and Body Mass Index in Patients with NSCLC Harboring EGFR Mutations (ID 1681)

    09:30 - 09:30  |  Author(s): T. Ishizuka
    • Abstract
    • Slides

    Background:
    Gefitinib is effective as first-line chemotherapy for advanced non-small cell lung cancer (NSCLC) patients harboring sensitive epidermal growth factor receptor (EGFR) mutations. Exon 19 deletions and the L858R point mutation are the most commonly encountered sensitive EGFR mutations in NSCLC, and have been shown to predict greater efficacy of gefitinib therapy. The objective of this study was to evaluate whether body surface area (BSA), body weight (BW), and body mass index (BMI) affect the efficacy of gefitinib in patients with NSCLC harboring sensitive EGFR mutations.
    
    Methods:
    We reviewed the medical charts of consecutive patients with advanced NSCLC harboring sensitive EGFR mutations who received gefitinib. The median values were used as the cutoffs to evaluate the impact of BSA and BW on the efficacy of gefitinib. BMI was categorized as underweight (BMI < 18.5 kg/m[2]), normal weight (BMI 18.5 to < 25 kg/m[2]), and overweight (BMI ≥ 25 kg/m[2]).
    
    Results:
    The median BSA and BW of the 138 NSCLC patients harboring sensitive EGFR mutations were 1.48 m[2] and 53 kg, respectively. The overall response rate, progression-free survival (PFS), and overall survival (OS) were 65.2%, 12.2 months, and 24.2 months, respectively. There were no significant differences in clinical outcomes between the high-BSA (BSA ≥ 1.43 m[2]) and low-BSA groups (BSA < 1.43 m[2]), with response rates of 68.5% and 72.0% (p = 0.92), median PFS of 12.2 and 11.5 months (p = 0.73), and median OS of 25.0 and 21.9 months, respectively (p = 0.28). Moreover, there were no significant differences in clinical outcomes between the high-BW (BW ≥ 53 kg) and low-BW groups (BW < 53 kg), with response rates of 63.3% and 67.1% (p = 0.72), median PFS of 12.2 and 10.8 months (p = 0.46), and median OS of 28.9 and 21.9 months, respectively (p = 0.22). For BMI, the median PFS and OS estimated among underweight, normal weight, and overweight patients were 10.6 and 19.2 months, 12.0 and 23.3 months, and 13.1 and 33.1 months, respectively. There were no statistically significant differences in PFS and OS among underweight, normal weight, and overweight patients (p = 0.52 and p = 0.30, respectively). Finally, to substantiate possible differences in the efficacy in patients who are young (<75 years) vs. elderly (≥ 75 years) and who have exon 19 deletions vs. L858R, we also evaluated these subgroups separately regarding BSA, BW, and BMI. However, there were no significant differences in the PFS and OS between these groups.
    
    Conclusion:
    The efficacy of gefitinib in patients with NSCLC harboring sensitive EGFR mutations does not differ according to their BSA, BW, and BMI.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.